Jennifer R. Brown

Broad Institute — United States

Medicine · Health Sciences

89h-index43.5kcitations1.2kworks2.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chronic Lymphocytic Leukemia Research(879), Lymphoma Diagnosis and Treatment(447), Immunodeficiency and Autoimmune Disorders(170), Chronic Myeloid Leukemia Treatments(137), Advanced Breast Cancer Therapies(97)

Publications1.2k total

Abstract B010: Determining the cancer cell sensitivity to IPMK-ATP competitive inhibitors
Cancer Research·2025
Supplementary Figures S1-8 from METTL3-Mediated m<sup>6</sup>A Modification Controls Splicing Factor Abundance and Contributes to Aggressive CLL
2025Open Access
Supplementary Tables S1-5 from METTL3-Mediated m<sup>6</sup>A Modification Controls Splicing Factor Abundance and Contributes to Aggressive CLL
2025Open Access
Multi-proteomic analyses provide evidence for origin of a co-existing serum monoclonal gammopathy in CLL/MBL
Blood·2025Open Access
Rituximab and epcoritamab as first-line therapy for patients with high-tumor burden follicular lymphoma: Results of a multicenter phase II trial
Blood·2025
Nodal progression in CLL: Real-world predictors of richter transformation and identification of a distinct high-risk NP-CLL subgroup
Blood·2025Open Access
Evaluation of ventoclax initiation prophylaxis and monitoring outcomes at each dose level and time point in patients with chronic lymphocytic leukemia: A real-world experience
Blood·2025Open Access
Pirtobrutinib in Relapsed/Refractory (R/R) Waldenström macroglobulinemia (WM): Up to 5 years of follow-up from the Phase 1/2 BRUIN study
Blood·2025
Glofitamab and obinutuzumab (GLOBIN) as first-line therapy for patients with high-tumor burden follicular lymphoma: First results of a multicenter phase II trial
Blood·2025Open Access
Roginolisib (IOA-244), an orally bioavailable, selective PI3Kδ inhibitor, in combination with venetoclax and rituximab in patients with relapsed chronic lymphocytic leukemia (CLL)
Blood·2025Open Access
Outcomes and prognostic factors in patients with follicular lymphoma treated with front-line bendamustine and rituximab
Blood·2025Open Access
Characterization of IGHV subgroups and their prognostic relevance in CLL
Blood·2025Open Access
Number needed to treat to avoid progression or death: Zanubrutinib vs other COVALENT bruton tyrosine kinase inhibitors in Relapsed/Refractory chronic lymphocytic leukemia
Blood·2025
Acquisition of CLL-like epigenetic and transcriptomic states in low-count MBL
Blood·2025Open Access
Systematic molecular profiling to identify determinants of response to ibrutinib
Blood·2025Open Access
Zanubrutinib + venetoclax for treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), including patients with del(17p) and/or TP53 mutation and unmutated immunoglobulin heavy-chain variable status: 3-year results from SEQUOIA arm D
Blood·2025Open Access
Phase I/II study of acalabrutinib, venetoclax, and obinutuzumab in patients with relapsed/refractory and previously untreated Mantle Cell Lymphoma (MAVO)
Blood·2025· 1 citedOpen Access
Symptom-based progression-free survival (S-PFS) as a clinically relevant and patient-centric endpoint in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Results from the ALPINE trial
Blood·2025
SF3B1 mutations are associated with shorter time to first treatment in chronic lymphocytic leukemia
Blood·2025
Estimated cardiac deaths associated with treating chronic lymphocytic leukemia with ibrutinib versus zanubrutinib in the United States
Blood·2025
page 1 of 58Next →

Frequent Co-authors

Steven Coutré(12), Richard R. Furman(12), Matthew S. Davids(11), Thomas J. Kipps(11), Peter Hillmen(11), Susan O’Brien(10), Constantine S. Tam(10), Stacey M. Fernandes(9), John M. Pagel(8), William G. Wierda(8), Jacqueline C. Barrientos(8), Donna Neuberg(8), Jennifer A. Woyach(8), John C. Byrd(8), Gad Getz(7), Catherine J. Wu(7), Ian W. Flinn(7), Paul M. Barr(6), Lili Wang(6), Paolo Ghia(6)